Disclosures for "Emboguard Balloon Guide Catheter in Stroke Thrombectomy: Procedural Insights and Outcomes"
-
Dr. Mahat has nothing to disclose.
-
Miss Almast has nothing to disclose.
-
Mr. Doheim has nothing to disclose.
-
Dr. Dwairi has nothing to disclose.
-
Abdullah Al Qudah has nothing to disclose.
-
Dr. Rios Rocha has nothing to disclose.
-
The institution of Dr. Rocha has received research support from NIH.
-
Dr. Bhatt has nothing to disclose.
-
Dr. Starr has nothing to disclose.
-
Dr. Lang has nothing to disclose.
-
Dr. Gross has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Dr. Gross has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Microvention. Dr. Gross has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AHA.
-
Dr. Nogueira has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Hybernia, Imperative Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby, and Synchron (consulting fees) as well as for advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, Vesalio, Viz-AI, RapidPulse and Perfuze ( stock options). Dr. Nogueira has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Law Firms. Dr. Nogueira has received stock or an ownership interest from Viz-AI, Perfuze, Cerebrotech, Reist/Q'Apel Medical, Truvic, and Viseon. The institution of Dr. Nogueira has received research support from Cerenovus.
-
Dr. Al-Bayati has nothing to disclose.